Top

Drug Safety

Published in:

01-08-2011 | Original Research Article

Rates of Spontaneous Reports of Adverse Drug Reactions for Drugs Reported in Children

A Cross-Sectional Study with Data from the Swedish Adverse Drug Reaction Database and the Swedish Prescribed Drug Register

Authors: Dr Susanna M. Wallerstedt, MD, PhD, Gertrud Brunlöf, Anders Sundström

Published in: Drug Safety | Issue 8/2011

Abstract

Background: Knowledge of drug safety is limited in the paediatric population, especially for drugs not used as labelled. Spontaneous reporting of adverse drug reactions (ADRs) may be an important source for increased knowledge, but the extent of the overall rate of reporting in children is not known.

Objective: The main objective of the study was to determine the extent of the spontaneous reporting of ADRs in children with a focus on drugs not used as labelled; this involved investigations of reporting rates of individual case safety reports (ICSRs) per 1000 treated individuals for drugs reported in children, to compare these between drugs labelled and not labelled for use in children, and to compare the rates for children with those of adults.

Methods: ICSRs (extracted from the Swedish ADR database) and number of treated individuals (extracted from the Swedish Prescribed Drug Register) were analysed for a 2-year period (2006–7). For drugs with one or more ICSR regarding children, rates of ICSRs per 1000 treated individuals were determined and compared between children (<18 years of age) and adults (≥18 years of age). Reported drugs for which >10% of the volume was sold over-the-counter or for in-hospital use were excluded. The overall reporting ratio of aggregated ICSRs per 1000 treated individuals was calculated between drugs not labelled and drugs labelled for use in children, separately for children and adults. The overall reporting ratio was also calculated between children and adults, separately for drugs labelled and drugs not labelled for use in children.

Results: A total of 255 (children) and 1402 (adults) ICSRs concerning 94 drugs were included in the analysis. Seventy-four (29%) and 711 (51%) ICSRs in children and adults, respectively, were registered as serious (p <0.00001, two-sided test of proportions). For drugs reported in three or more ICSRs regarding children, the rates of ICSRs per 1000 treated individuals varied between (range) 0.01–6.45 (children) and 0.01–6.39 (adults). For 17 of the drugs (18%) the rates of ICSRs per treated individual were significantly higher for children than for adults, and for 2 of the drugs (2%) the result was the opposite. The overall comparison of aggregated ICSRs per 1000 treated children revealed a higher reporting rate for drugs not labelled than for drugs labelled for children: rate ratio 3.44 (95% CI 2.67, 4.43); p<0.00001. The corresponding result for adults was 1.52 (95% CI 1.37, 1.68); p< 0.00001. The overall reporting rate of aggregated ICSRs per 1000 treated individuals was higher in children than adults for drugs not labelled for children: rate ratio 2.01 (95% CI 1.61, 2.51); p< 0.00001.

Conclusions: The results of the present study indicate that the extent of the reporting of ADRs is greater for drugs not labelled for children than for drugs labelled for children. For these drugs, the extent of the reporting is greater for children than for adults. Thus, healthcare personnel willingly report ADRs in children, especially ADRs for drugs used outside the terms of the product licence. The finding is reassuring since there are few other sources for knowledge of paediatric drug safety. Important limitations of the study are (i) only a few ICSRs were registered for most drugs, thus giving each ICSR a strong impact on the rates for individual drugs; and (ii) the results of the present study apply only to the drugs included in the analysis.

Sturkenboom MC, Verhamme KM, Nicolosi A, et al. Drug use in children: cohort study in three European countries. BMJ 2008; 337: a2245PubMedCrossRef

Impicciatore P, Choonara I, Clarkson A, et al. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001; 52(1): 77–83PubMedCrossRef

Kimland E, Rane A, Ufer M, et al. Paediatric adverse drug reactions reported in Sweden from 1987 to 2001. Pharmacoepidemiol Drug Saf 2005; 14(7): 493–9PubMedCrossRef

Moore TJ, Weiss SR, Kaplan S, et al. Reported adverse drug events in infants and children under 2 years of age. Pediatrics 2002; 110(5): e53PubMedCrossRef

Buajordet I, Wesenberg F, Brors O, et al. Adverse drug events in children during hospitalization and after discharge in a Norwegian university hospital. Acta Paediatr 2002; 91(1): 88–94PubMedCrossRef

Easton KL, Chapman CB, Brien JA. Frequency and characteristics of hospital admissions associated with drug-related problems in paediatrics. Br J Clin Pharmacol 2004; 57(5): 611–5PubMedCrossRef

Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002; 87(6): 462–6PubMedCrossRef

Ufer M, Kimland E, Bergman U. Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. Pharmacoepidemiol Drug Saf 2004; 13(3): 147–52PubMedCrossRef

Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 2002; 54(6): 665–70PubMedCrossRef

10.

Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000; 320(7227): 79–82PubMedCrossRef

11.

Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions. Arch Intern Med 2005; 165(12): 1363–9PubMedCrossRef

12.

Medical Products Agency. Code of statutes. Uppsala: Medical Products Agency, 2006

13.

WHO Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre. Glossary of terms used in pharmacovigilance [online]. Available from URL: http://whoumc.org/Graphics/24729.pdf [Accessed 2011 Jun 17]

14.

Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 2008; 7(1): 21–39PubMedCrossRef

15.

WHO Collaborating Centre for Drug Statistics and Methodology. ATC/DDD index 2011 [online]. Available from URL: http://www.whocc.no/atc_ddd_index/ [Accessed 2011 Jun 17]

16.

van der Hooft CS, Sturkenboom MC, van Grootheest K, et al. Adverse drug reaction-related hospitalisations: a nationwide study in the Netherlands. Drug Saf 2006; 29(2): 161–8PubMedCrossRef

17.

Turner S, Nunn AJ, Fielding K, et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999; 88(9): 965–8PubMedCrossRef

18.

Neubert A, Dormann H, Weiss J, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf 2004; 27(13): 1059–67PubMedCrossRef

19.

McLay JS, Tanaka M, Ekins-Daukes S, et al. A prospective questionnaire assessment of attitudes and experiences of off label prescribing among hospital based paediatricians. Arch Dis Child 2006; 91(7): 584–7PubMedCrossRef

20.

Ekins-Daukes S, Helms PJ, Taylor MW, et al. Off-label prescribing to children: attitudes and experience of general practitioners. Br J Clin Pharmacol 2005; 60(2): 145–9PubMedCrossRef

21.

Aagaard L, Weber CB, Hansen EH. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007. Drug Saf 2010; 33(4): 327–39PubMedCrossRef

22.

Wallerstedt SM, Brunlof G, Sundstrom A, et al. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf 2009; 18(9): 858–64PubMedCrossRef

23.

Wysowski DK, Swartz L. Relationship between headache and depression in users of isotretinoin. Arch Dermatol 2005; 141(5): 640–1PubMedCrossRef

24.

Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000; 136(10): 1231–6PubMedCrossRef

25.

Azoulay L, Blais L, Koren G, et al. Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study. J Clin Psychiatry 2008; 69(4): 526–32PubMedCrossRef

26.

Belton KJ. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group. Eur J Clin Pharmacol 1997; 52(6): 423–7PubMedCrossRef

27.

Clark RC, Maxwell SR, Kerr S, et al. The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions. Drug Saf 2007; 30(4): 357–66PubMedCrossRef

28.

Bégaud B. Statistical methods of evaluating pharmacovigilance data. In: Mann RD, Andrews EB, editors. Pharmacovigilance. John Wiley & Sons, 2002: 281–9

29.

Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994; 10(2): 93–102PubMedCrossRef

30.

Bate A, Lindquist M, Orre R, et al. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs. Eur J Clin Pharmacol 2002; 58(7): 483–90PubMedCrossRef

31.

Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10(6): 483–6PubMedCrossRef

32.

Bourgeois FT, Mandl KD, Valim C, et al. Pediatric adverse drug events in the outpatient setting: an 11-year national analysis. Pediatrics 2009; 124(4): e744–50PubMedCrossRef

Title: Rates of Spontaneous Reports of Adverse Drug Reactions for Drugs Reported in Children
A Cross-Sectional Study with Data from the Swedish Adverse Drug Reaction Database and the Swedish Prescribed Drug Register
Authors: Dr Susanna M. Wallerstedt, MD, PhD
Gertrud Brunlöf
Anders Sundström
Publication date: 01-08-2011
Publisher: Springer International Publishing
Published in: Drug Safety / Issue 8/2011
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI: https://doi.org/10.2165/11591730-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Rates of Spontaneous Reports of Adverse Drug Reactions for Drugs Reported in Children

A Cross-Sectional Study with Data from the Swedish Adverse Drug Reaction Database and the Swedish Prescribed Drug Register

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2011

Conflicts of Interest in Medicines Safety and Regulation

Safety Considerations in Drug Treatment of Depression in HIV-Positive Patients

Clarity and Applicability of Drug-Drug Interaction Management Guidelines

Drug Treatment for Obesity in the Post-Sibutramine Era

The Fatal Love of Forms

Associate Professor David W.J. Clark 1940–2011